Benjamin G. Neel, M.D., Ph.D.
Working to cure cancer in our lifetime.
My own research focuses on cellular signaling pathways regulating normal cell proliferation and differentiation, and how disruption of these pathways can cause human diseases, especially cancer. I have a particular interest in the biology and regulation of specific molecules called protein-tyrosine phosphatases which are involved in many normal cell functions. I also study the role of RAS/ERK pathway mutations in developmental diseases and cancer, and the biology of breast and ovarian cancers.
I am a member of the National Academy of Sciences, the American Academy of Physicians, and the Royal Society of Canada (Foreign Member).
Lighthorse Therapeutics, Co-Founder and SAB member
Kojin Therapeutics, SAB Member
Navire Pharma, Co-founder and SAB member
Northern Biologics, Co-founder. Acquired by Boehringer Ingelheim in May, 2020
Arvinas, Inc., SAB Member
Recursion, SAB Member
Director (2015 - 2023)
NYU School of Medicine
Professor, Department of Medicine (2015 - present)
Associate Dean for Cancer Research (2022 - 2023)
The Campbell Family Institute for Cancer Research, Toronto, ON
Founding Director (2008 - 2014)
Princess Margaret Hospital Cancer Center, Toronto, ON
Director, Research (2007 - 2014)
University of Toronto, Toronto, ON
Professor of Medical Biophysics (2007 - 2015)
Canada Research Chair, Tier 1 (2007 - 2015)
Beth Israel Deaconess Medical Center, Boston, MA
Deputy Director, Basic Research, Hematology/Oncology Division (2003 - 2007)
Director, Cancer Biology Program (1994 - 2007)
Harvard Medical School, Boston, MA
William B. Castle Professor of Medicine (2006 - 2007)
Professor of Medicine (1999 - 2007)
Associate Professor of Medicine (1993 - 1999)
Assistant Professor of Medicine (1988 - 1993)